1Guy B, Almond WJ. Towards a dengue vaccine: Progress to date and remaining challenges [J]. Comp Immunol Microbol Infect Dis, 2008,31 (2-3) : 239-252.
2Whitehead SS, Blaney JE, Durbin AP, et al. Prospects for a dengue virus vaccine [ J ]. Nature, 2007,5 : 518-528.
3Edelman R, Wasserman SS, Bodison SA, et al. Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine [J]. Am J Trop Med Hyg, 2003,69(6 suppl):45-60.
4Purl B, Nelson WM, Henchal EA, et al. Molecular analysis of dengue virus attenuation after serial passage in primary dog kidney cell [J]. J Gen Virol, 1997,78:2287-2291.
5Sabehareon A, Lang J, Chanthavanich P, et al. Safety and immunogenicity of a three dose regimen of two tetmvalent live .attenuated dengue vaccines in five-to twelve-year-old Thai children [J]. Pediatr Infect Dis J, 2004,23 (2) :99-109.
6Kitchener S, Nissen M, Nasveld P, et al. Immunogenicity and safety of two live-attenuated teravalent dengue vaccine formulations in healthy Australian adults[J]. Vaccine, 2006, 24: 1238-1241.
7Kanesa-Thasan N, Edelman R, Tacket CO, et al. Phase 1 stuies of Walter Reed Army Institute of Research can didate attenuted dengue vaccines: selection of safe and immunogenic monovalent vaccines [J]. Am J Trop Med Hyg, 2003,69 (Suppl 6) : 17-23.
8Hombach J, Cardosa M J, Sabchareon A, et al. Scientific consultation on immunological correlates of protection induced by dengue vaccinesnext termstar, open Report from a meeting held at the World Health Organization 17-18 November 2005 [J]. Vaccine, 2007,25(21 ) :4130-4139.
9Bhamarapravati N, Sutee Y. Live attenuated tetravalent dengue [J]. Vaccine, 2000,18(Suppl 2) :44-47.
5Chambers TJ.Vaccine development against dengue and Japanese encephalitis:report of a World Health Organization meeting[J].Vaccine,1997,15(14):1494-1502.
6Sabchareon A,Lang J,Chanthavanich P,et al.Safety and immunogenicity of tetravalent live-attenuated dengue vaccines in Thai adult volunteers:role of serotype concentration,ratio,and multiple doses[J].Am J Trop Med Hyg,2002,66(3):264 -272.
7Sabchareon A,Lang J,Chanthavanich P,et al.Safety and immunogenicity of a three dose regimen of two tetravalent live-attenuated dengue vaccines in five-to twelve-year-old Thai children[J].Pediatr Infect Dis J,2004,23 (2):99-109.
8Eckels KH,Dubois DR,Putnak R,et al.Modification of dengue virus strains by passage in primary dog kidney cells:preparation of candidate vaccines and immunization of monkeys[J].Am J Trop Med Hyg,2003,69 (Suppl 6):12-16.
9Kanesa-Thasan N,Edelman R,Tacket CO,et al.Phase 1 studies of Walter Reed Army Institute of Research candidate attenuated dengue vaccines:selection of safe and immunogenic monovalent vaccines[J].Am J Trop Med Hyg,2003,69 (Suppl 6):17-23.
10Sun W,Edelman R,Kanesa-Thasan N,et al.Vaccination of human volunteers with monovalent and tetravalent live-attenuated dengue vaccine candidates[J].Am J Trop Med Hyg,2003,69(Suppl 6):24 -31.
